Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

Fig. 3

Adjusted vaccine effectiveness against infection (A) and hospitalisation (B) per vaccine product regimen (Spikevax (blue), Comirnaty (pink), or mixed mRNA primary regimen (dark green) and mixed booster (light green and yellow) amongst Norwegian adults using data from 15 July to 30 November 2021. Adjusted for age, sex, comorbidities, county of residence, country of birth and living conditions. mRNA includes a combination of one dose Spikevax and one dose Comirnaty; only few individuals who received a heterologous primary regimen were eligible for a booster during the study period and are therefore not included

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us